Interference of Lumican Regulates the Invasion and Migration of Liver Cancer Cells
Abstract
To explore the effect of silencing lumican on the invasion and migration of liver cancer cells. Methods Lumican was silenced by shRNA in liver cancer cells (HepG2 and MHCC97H). The mRNA levels of lumican were detected by qRT-PCR. Cell invasion was measured by Transwell. Cell migration was tested via wound healing. The protein levels of lumican, MMP-9, VEGF, ERK1, JNK, p-ERK1 and p-JNK were measured by Western blot. Results Liver cancer cells (HepG2 and MHCC97H) had higher levels of mRNA and protein of lumican compared with normal hepatocyte L02 (P<0.01). shRNA lowered the levels of mRNA and protein of lumican (P<0.01), and weakened the invasion and migration of cancer cells (P<0.01). The expressions of MMP-9 and VEGF decreased with the shRNA silence (P<0.01). shRNA also reduced the protein level of p-ERK1 and p-JNK (P<0.01). Conclusion Silencing lumican by shRNA attenuates the invasion and migration of liver cancer cells via inhibiting the activation of ERK1/JNK pathway.
Keywords: Liver cancer lumican shRNA, Invasion, Migration, ERK1/JNK pathway
Full Text:
PDFReferences
FERLAYJ. SOERJOMATARAM I, DIKSHIT R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer,2015, 136(5): E359-E386.
TORRE LA, BRAY F, SIEGEL RL. et al. Global cancer statistics, 2012. CA Cancer J Clin,2015,65(2) ;87-108.
CHEN W, ZHENG R, ZUO T, et al. National cancer incidence and mortality in China, 2012. Chin J Cancer Res, 2016*28(1):1-11.
WEI KR, YU X, ZHENG RS,et al. Incidence and mortality of liver cancer in China, 2010. Chin J Cancer, 2014 , 33 (8); 388-394.
CHEN W, ZHENG R, BAADE PD,et al. Cancer statistics in China, 2015. С A Cancer J Clin, 2016,66(2): 115-132.
BAGHY K, TATRAI P, REGOS E,et al. Proteoglycans in liver cancer. World J Gastroenterol ,2016 ,22(1); 379-393.
AMJADI S, MAI K. The role of lumican in ocular disease. ISRN Ophthalmol, 2013: 632302 [2017-11-17]. http://dx. doi. org/10. 1155/2013/632302.
HALPER J. Proteoglycans and diseases of soft tissues. Adv Exp Med Biol,2014,802:49-58.
HSIEH LT, NASTASE MV, ZENG-BROUWERS J,ei al. Soluble biglycan as a biomarker of inflammatory renal diseases. Int J Biochem Cell Idiol ,2014,54 :223-235[2017-11- 17]. https;//doi. org,/10. 1016/j. biocel. 2014. 07. 020.
PIETRASZEK К, CHATRON-COLLIET A, BREZILLON S, et al. Lumican: a new inhibitor of matrix metalloproteinase-14 activity. FEBS Lett, 2014, 588 ( 23 ) : 4319-4324.
LIU CY, CHP:N KF, CHEN PJ. Treatment of liver cancer. Cold Spring Harb Perspect Med.2015,5(9) ;a021535.
CHOIKJ, В AIK IH, YE SK, et al. Molecular targeted therapy for hepatocellular carcinoma; present status and future directions. Biol Pharm Bull.2015,38(7) ;986-991.
VYNIOS DH. Metabolism of cartilage proteoglycans in health and disease. Biomed Res Int, 2014 ; 452315 [2017-11- 17]. http://dx. doi. org/10. 1155/2014/452315.
ZHANG GL, ZHANG X, WANG XM, et al. Towards understanding the roles of heparan sulfate proteoglycans in Alzheimer's disease. Biomed Res Int.2014 :516028[2017-11- 17]. http://dx. doi. org/10. 1155/2014/516028.
WADE A, ROBINSON AE, ENGLER JR, et al. Proteoglycans and their roles in brain cancer. Febs J,2013, 280(10):2399-2417.
TAKAYAMA R, ANSA I S, ISHIWATA T, et al. Expression of lumican in hidroacanthoma simplex and clonal- type seborrheic keratosis as a potent differential diagnostic marker. Am J Dermatopathol,2014 ,36(8) ;655-660.
LIU XJ, KONG FZ, WANG YH,et al. Lumican Accelerates Wound Healing by Enhancing alpha2betal Integrin-Mediated Fibroblast Contractility. PLoS One, 2013, 8 (6): e67124 [2017-11-17]. https;//doi. org/10. 1371/journal, pone. 0067124.
LU ХМ, MA L, JIN YN, et al. Lumican overexpression exacerbates lipopolysaccharide-induced renal injury in mice. Mol Med Rep.2015,12(3) ;4089-4094.
CAPPELLESSO R, MILLIONI R, ARRIGONI G, et al. Lumican is overexpressed in lung adenocarcinoma pleural effusions. PLoS One, 2015,10 ( 5): e0126458[2017-11-17]. https;//doi. org,/10. 1371/journal, pone. 0126458.
ENGEBRETSEN KV, LUNDE IG, STRAND ME. et al. Lumican is increased in experimental and clinical heart failure, and its production by cardiac fibroblasts is induced by mechanical and proinflammatory stimuli. Febs J, 2013, 280 (10):2382-2398.
APPUNNI S, ANAND V, KHANDELWAL M, et al. Altered expression of small leucine-rich proteoglycans ( Decorin, Biglycan and Lumican); Plausible diagnostic marker in urothelial carcinoma of bladder. Tumour Biol. 2017, 39 ( 5 ): 1010428317699112 [2017-11-17]. http:// journals, sagepub. com,/doi/10. 1177/1010428317699112.
THEOC HARIS AD, SK AND A LIS SS, NEILL T, et al. Insights into the key roles of proteoglycans in breast cancer biology and translational medicine. Biochim Biophys Acta, 2015,1855(2);276-300.
LIM HC. MULTHAUPT HA, COUCHMAN JR. Cell surface heparan sulfate proteoglycans control adhesion and invasion of breast carcinoma cells. Mol Cancer, 2015, 14: 15 [2017-11-17]. https://doi. org/10. 1186/sl2943-014-0279-
WUH. JING X, CHENG X, et al. Asporin enhances colorectal cancer metastasis through activating the EGFR src/cortactin signaling pathway. Oncotarget, 2016, 7 ( 45 ); 73402-73413.
Refbacks
- There are currently no refbacks.
